A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety
and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative
subjects with Chronic Hepatitis B.